The DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index.
Interleukin (IL-6) Immunotherapy
Open accessAbstract
Interleukin 6 (IL-6) is a prototypical cytokine for maintaining homeostasis. When homeostasis is disrupted by infections or tissue injuries, IL-6 is produced immediately and contributes to host defense against such emergent stress through activation of acute-phase and immune responses. However, dysregulated excessive and persistent synthesis of IL-6 has a pathological effect on, respectively, acute systemic inflammatory response syndrome and chronic immune-mediated diseases. The IL-6 inhibitor, tocilizumab, a humanized anti-IL-6 receptor antibody, is currently being used for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, and Castleman disease. Lines of recent evidence strongly suggest IL-6 blockade can provide broader therapeutic strategy for various diseases included in acute systemic and chronic inflammatory diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
IL‐6 in inflammation, immunity, and disease
Tanaka, T., Narazaki, M., & Kishimoto, T. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a016295 · Cited by 5,046
Self-citationChimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
Singh, J. A., Saag, K. G., Bridges, S. L., Akl, E. A., Bannuru, R. R., Sullivan, M. C., Vaysbrot, E., McNaughton, C., Osani, M., Shmerling, R. H., et al. (2016) · Arthritis & Rheumatology · doi:10.1002/art.39480 · Cited by 2,777
Interleukin-6 and the acute phase response
Heinrich, P. C., Castell, J. V., & Andus, T. (1990) · Biochemical Journal · doi:10.1042/bj2650621 · Cited by 2,734
Nemeth, E., Rivera, S., Gabayan, V., Keller, C., Taudorf, S., Pedersen, B. K., & Ganz, T. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420945 · Cited by 2,650 · cited 1×
“Moreover, IL-6-induced hepcidin production blocks the action of iron transporter ferroportin 1 on gut and thus reduces serum iron levels (Nemeth et al. 2004), resulting in hypoferremia and anemia associated with chronic inflammation.”
BackgroundCytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa063842 · Cited by 2,164 · cited 1×
“Surgery-related complications, adrenal insufficiency, pulmonary embolism, and aortic aneurysm can also lead to SIRS, and a biological drug against CD28 was also reported to induce SIRS (Suntharalingam et al. 2006).”
BackgroundHirano, T., Yasukawa, K., Harada, H., Taga, T., Watanabe, Y., Matsuda, T., Kashiwamura, S.-I., Nakajima, K., Koyama, K., Iwamatsu, A., et al. (1986) · Nature · doi:10.1038/324073a0 · Cited by 2,139 · cited 1×
“The human IL-6 gene was first cloned as B-cell stimulatory factor 2 (BSF-2), which induces B cells to produce immunoglobulin (Ig) (Kishimoto 1985; Hirano et al. 1986).”
BackgroundSelf-citationKishimoto, T. (1989) · Blood · doi:10.1182/blood.v74.1.1.1 · Cited by 2,069
Self-citationSmolen, J. S., Landewé, R., Bijlsma, J., Burmester, G., Chatzidionysiou, K., Dougados, M., Nam, J., Ramiro, S., Voshaar, M., van Vollenhoven, R., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210715 · Cited by 2,057
Cited by
Interplay between interleukin-6 signaling and the vascular endothelium in cytokine storms
Kang, S., & Kishimoto, T. (2021) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00649-0 · Cited by 375
Self-citationCritical Determinants of Cytokine Storm and Type I Interferon Response in COVID-19 Pathogenesis
Ramasamy, S., & Subbian, S. (2021) · Clinical Microbiology Reviews · doi:10.1128/cmr.00299-20 · Cited by 289
Interleukin-6: obstacles to targeting a complex cytokine in critical illness
McElvaney, O. J., Curley, G. F., Rose-John, S., & McElvaney, N. G. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00103-x · Cited by 278
Roberts, M. B., & Fishman, J. A. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1189 · Cited by 277
Dynamic lipidome alterations associated with human health, disease and ageing
Hornburg, D., Wu, S., Moqri, M., Zhou, X., Contrepois, K., Bararpour, N., Traber, G. M., Su, B., Metwally, A. A., Avina, M., et al. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00880-1 · Cited by 260
Lee, Y. E., Go, G.-Y., Koh, E.-Y., Yoon, H.-N., Seo, M., Hong, S.-M., Jeong, J. H., Kim, J.-C., Cho, D., Kim, T. S., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006130 · Cited by 61
Lysosomal amino acid transporters as key players in inflammatory diseases
Toyama-Sorimachi, N., & Kobayashi, T. (2021) · International Immunology · doi:10.1093/intimm/dxab069 · Cited by 14
Metadata
- Authors
- Tanaka, T., Narazaki, M., & Kishimoto, T.
- Venue
- Cold Spring Harbor Perspectives in Biology
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2017-08-04
- Volume
- 10
- Issue
- 8
- Pages
- a028456
- ISSN
- 1943-0264 (ISSN-L)
- OpenAlex
- W2744892122
- Cited by
- 407
- References
- 83
- Type
- posted content
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.